Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details. The only financial figure disclosed is the transaction price of £12.83 per ordinary share.
Material Changes
The material change reported is an increase in shareholdings for specific individuals following the re-investment of dividends paid to shareholders on January 8, 2009. The specific increases are as follows:
- Mr A P Witty: 26 shares
- Mrs C M Witty: 357 shares
- Mr J S Heslop: 187 shares
- Mrs P A Heslop: 303 shares
- Mr D Learmouth: 153 shares
- Dr D Pulman: 162 shares
- Mrs C R Pulman: 54 shares
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The notification relates to a transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by the named directors and connected persons prior to this transaction to assess total ownership concentration.
- Confirm the dividend amount per share paid on January 8, 2009, to validate the reinvestment calculation.
- Review the company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial statements.